Brandon Zipp serves as the Chief Science Officer and Scientific Co-founder at Graphium Biosciences, where he plays a pivotal role in shaping the future of cannabinoid-based pharmaceuticals. With a diverse background in biotechnology, Brandon excels at leading multidisciplinary teams through the complexities of drug development,...
Brandon Zipp serves as the Chief Science Officer and Scientific Co-founder at Graphium Biosciences, where he plays a pivotal role in shaping the future of cannabinoid-based pharmaceuticals. With a diverse background in biotechnology, Brandon excels at leading multidisciplinary teams through the complexities of drug development, from ideation to pre-clinical trials. His expertise spans critical areas such as metabolic engineering, fermentation processes, and medicinal chemistry, enabling him to drive innovative solutions in the rapidly evolving field of glycobiology and cannabinoid research.
At Graphium, Brandon is at the forefront of several key projects, focusing on the development of next-generation therapeutics that leverage the unique properties of cannabinoids and plant secondary metabolites. He manages a dynamic pre-clinical development pipeline, overseeing internal and external R&D efforts while ensuring compliance with regulatory submissions and intellectual property considerations. His hands-on experience in pilot-scale manufacturing and ADME/PK studies allows him to navigate the challenges of scaling up production while maintaining the integrity and efficacy of the compounds being developed.
Brandon's scientific acumen is complemented by his strong project management skills, enabling him to effectively coordinate cross-functional teams and foster collaboration across various disciplines. His proficiency in bioinformatics and next-generation sequencing further enhances the research capabilities at Graphium, allowing for data-driven decision-making in the pursuit of groundbreaking therapies. As a passionate advocate for innovation in biotechnology, Brandon is profoundly grateful for the opportunity to contribute to advancements that have the potential to transform patient care and improve health outcomes.
